Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular, Oncologie Form Cancer Drug Biomarker Partnership

NEW YORK (GenomeWeb) — HTG Molecular Diagnostics announced today that it has signed a master agreement to help Oncologie develop biomarkers for its immuno-oncology drug candidates.

Specific terms of the deal were not disclosed.

Oncologie currently has two drugs in its pipeline: the phase II immune-modulatory monoclonal antibody bavituximab, and the phase III immunomodulator and toll-like receptor 9 agonist lefitolimod. HTG offers next-generation sequencing-based molecular profiling instruments and assays, as well as related lab services.

"We believe HTG's technology and assay development capabilities will assist our clinical development efforts as we strive to bring innovative new medicines to cancer patients globally," Oncologie Founder and CEO Laura Benjamin said in a statement.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.